Resmed Announces Agreement to Sell MatrixCare Business
Key points
- Resmed to sell MatrixCare business to Frazier Healthcare Partners for $490 million in cash
- Transaction expected to close in Q1 of fiscal year 2027
- Proceeds to be used for share repurchases and general corporate purposes
Full summary
Resmed Inc. has announced its decision to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in cash. This strategic move aligns with Resmed's 2030 strategy to focus on high-growth opportunities in sleep health, breathing health, and connected home-based healthcare. The MatrixCare business, which provides software solutions to over 15,000 providers, will continue to operate under Resmed until the transaction closes in Q1 of fiscal year 2027, subject to regulatory approvals and customary closing conditions. Resmed intends to use the net proceeds from the sale to return capital to shareholders and for general corporate purposes.
Guidance
Resmed expects to use net proceeds for share repurchases and general corporate purposes
Outlook
Resmed will provide its full fiscal year 2027 outlook during its fourth quarter fiscal year 2026 earnings call on August 6, 2026
Summary generated by a large language model. Please interpret with care.